GHW International
（incorporated in the Cayman Islands with limited liability）
(Stock Code: 9933.HK)
ENTERING INTO AN EXCLUSIVE DISTRIBUTION AGREEMENT FOR MEDICAL OPTICAL LENSES
EXPAND THE NEW LANDSCAPE OF HEALTH TECHNOLOGY
[December 20, 2024 - HONG KONG] Applied chemical intermediates provider in the integrated chemical services market – GHW International（「GHW」），together with its subsidiaries （the 「Group」） , Stock Code：9933.HK） announced today that, Nanjing Happyelephant Health Technology Co., Ltd. （「Nanjing Happyelephant」）, a subsidiary of GHW, entered into an exclusive distribution agreement with medical optical lenses manufacture, SWISSCOAT Vision（China）Limited（「SWISSCOAT」）to promote and sell SWISSCOAT（China Trademark「瑞士寶」）medical ophthalmology custom optical lenses in China in the future, signifies that the Group is moving further to the field of health technology.
Nanjing Happyelephant specialises in the development and sale of scientific functional and health foods. In 2024, Nanjing Happyelephant launched ingredients of glucosamine product and began to develop health products such as articular cartilage repair products. SWISSCOAT (Hong Kong) Limited, established in 1989, is a well-known domestic and foreign functional optical lens manufacturer with more than 30 years of experience in optical lens development and manufacturing. The cooperation will fully integrate the expertise and resource advantages of the two sides to achieve complementary development. n the future, Nanjing Happyelephant will make full use of its channel advantages and will use key channels such as specialized ophthalmology hospitals and comprehensive medical institution ophthalmology and optometry centers for marketing.
As of 2023, China has over 17 million people with visual impairments, accounting for 17% of the national disabled population (85.914 million) and approximately 18% of the global blind population, making it one of the countries with the highest number of visually impaired individuals worldwide. At the same time, due to the acceleration of modern life pace, the incidence of various eye diseases is also showing an increasing trend, further exacerbating the severity of visual impairment issues. China sees an annual increase of 450,000 blind people and 1.35 million people with low vision, involving different age groups such as children, adolescents, adults, middle-aged, and the elderly. The causes of low vision are becoming increasingly diversified, including but not limited to hereditary eye diseases (such as retinitis pigmentosa), glaucoma, diabetic eye diseases, cataracts/macular degeneration.
In this cooperation, the two sides will jointly promote the development and promotion of professional optical lens products for visually impaired people, including: bifocal lenses, low vision aids, extreme degree/high prism custom lenses, low vision rehabilitation aids, and medical photosensitive filters. These innovative products will provide professional and efficient vision solutions for visually impaired patients to meet their diverse segmented needs. Among them, the low vision rehabilitation aid can be applied to patients with severe lesions in the central area of macula. The prism function is used to change the target's imaging position on the retina, and specific MF medical color filters are added to filter irritating light to help improve the contrast and clarity of influence. Medical photosensitive filters can protect the eyes and enhance visual function, improve migraine symptoms and reduce incidence, reduce the incidence of epilepsy, and relieve visual dyslexia - Irlen photosensitivity syndrome.
This cooperation is another important step for the Group to further cultivate the health sector. The Group is committed to using its expertise and resource advantages to provide better health protection for a wider range of people. As a socially responsible company, the Group sees various challenges faced by people with visual impairment, and is therefore actively seeking opportunities to cooperate with Swiss Lenses to jointly promote more innovative products in the field of visual impairment. Looking forward to the future, the Group will continue to strengthen cooperation with the industry and promote products and technology globally through a wider range of channels and platforms. We believe that through this cooperation, the Group will be able to make better use of the company's strengths and potential in the field of health, make greater contributions to society, and achieve the sustainable development of the company.
– End –
About GHW International
GHW International is an applied chemical intermediates provider in the integrated chemical services market, mainly engaged in the production and sale of chemicals and the sale of chemicals produced by third party manufacturers located in mainland China, Southeast Asia, Europe and the United States.
Headquartered in mainland China, it provides a comprehensive and widely used product portfolio and a full range of services related to the chemical intermediate supply chain through a comprehensive global operation and sales network (including research and development of production processes, strong product customization capabilities, production of high-quality chemical products, procurement of various chemicals produced by third-party manufacturers, efficient and safe logistics services and after-sales services).
The business operation includes seven major business segments, including pharmaceutical intermediates and APIs, applied chemicals series, advanced material intermediates series, iodine derivatives series and ancillary products, methylamine industry series, Happy Elephant Universe, advanced medical and health products, and ESG industry.
For the six months ended June 30, 2024, the Group achieved revenue of 1.79 billion yuan (RMB, same below), an increase of 21.28% year-on-year; the profit attributable to shareholders is 4.447 million yuan, an increase of 404.77% year-on-year; and basic profit of 0.005 yuan per share.
